Generated by AI
Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its current portfolio includes treatments for movement disorders such as tardive dyskinesia and Huntington’s disease chorea, as well as therapies for endocrine conditions including congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company also maintains a clinical-stage pipeline spanning additional neuroscience and endocrine targets, with research programs aimed at addressing underserved patient populations. Neurocrine Biosciences, Inc. plays an important role in specialty pharmaceuticals by combining marketed products with ongoing drug development across complex, chronic conditions that often require long-term management. Headquartered in San Diego, California, it serves patients and healthcare providers in the United States and internationally through its commercial operations and development activities.
Website6027 Edgewood Bend Court
San Diego, CA, 92130
United States
The latest articles about NBIX.
Neurocrine Biosciences posts strong Q3 earnings as INGREZZA drives growth and rare disease expansion gains traction. Find out why NBIX stock is a buy.
Summary of Nov 3's posts. Generated by AI.
Summary of Nov 3's posts. Generated by AI.
Summary of Jun 2's posts. Generated by AI.
Summary of Nov 3's posts. Generated by AI.
Investors talking about NBIX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.